首页>
外国专利>
THERAPEUTIC TARGETED FUSION PROTEINS BASED ON LYSOSOMAL ENZYMES, RELEVANT COMPOSITIONS AND THEIR APPLICATIONS
THERAPEUTIC TARGETED FUSION PROTEINS BASED ON LYSOSOMAL ENZYMES, RELEVANT COMPOSITIONS AND THEIR APPLICATIONS
展开▼
机译：基于溶酶体酶，相关组合物及其应用的治疗靶向融合蛋白
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: biotechnology.;SUBSTANCE: invention relates to the field of biotechnology, more specifically to a composition for reducing or preventing glycosaminoglycan (GAG) accumulation in one or more CNS (central nervous system) tissues of the subject suffering from mucopolysaccharidosis of IIIB type; it can be used in medicine. The obtained composition contains fusion protein including functional enzyme alpha-N-acetylglucosaminidase (Naglu), spacer peptide and peptide mark based on insulin-like growth factor II of the human (IGF-II) at a concentration from 25 mg/ml to 35 mg/ml.;EFFECT: invention can be used in effective therapy of mucopolysaccharidosis of IIIB type.;81 cl, 12 dwg, 6 tbl, 4 ex
展开▼
机译：田地：生物技术。物质：发明领域涉及生物技术领域，更具体地涉及用于减少或预防患有IIIB型粘性多种粘多素病的一个或多个CNS（中枢神经系统）组织中的糖胺聚糖（GAG）积聚的组合物;它可以用作医学。所得组合物含有融合蛋白，包括基于人（IGF-II）的胰岛素样生长因子II的官能酶α-N-乙酰葡糖胺酶（NAGLU），间隔肽和肽标记，其浓度为25mg / ml至35mg /ml.Effect：发明可用于有效治疗IIIB型粘性多糖病。; 81 Cl，12 dwg，6 tbl，4 ex
展开▼
